CClinicalTrials.gg
CompletedNCT00879502Updated May 30, 2017

Examining Physiology and Brain Function in People With the Fragile X Premutation

An observational study in Fragile X Premutation, sponsored by University of California, Davis. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by University of California, Davis · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
110
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study will examine whether individuals with the fragile X genetic premutation are likely to have emotional, social, and memory deficits and how the brain may be involved in these deficits.

Read the detailed description

FMR1 is a gene associated with fragile X syndrome-the most common cause of mental retardation-and with social, emotional, and cognitive deficits. The chance of developing these deficits depends on the number of times the FMR1 gene is repeated on the X chromosome. Individuals with more than 200 copies of the FMR1 gene have the full fragile X mutation, putting them at most risk for mental retardation. Individuals with between 55 and 200 copies of the FMR1 gene have the fragile X premutation; they are much less likely to develop mental retardation, but they may have subtle social, emotional, and cognitive deficits and their children are more likely to have the full fragile X mutation. A theory, which this study will test, holds that the deficits of people with the fragile X premutation are caused by dysfunction in the limbic system. The limbic system consists of a group of structures in the brain that govern emotions and behavior. This study will examine people with the fragile X premutation to determine whether and to what extent they have emotional, social, and memory deficits. The study will also determine whether changes in fragile X gene function are related to increased deficits and how the brain, and specifically the limbic system, may be involved in these deficits.

Participation in this study will last 2 days. Participants will undergo several hours of testing at a lab on back-to-back days. Testing on the first day will include the following: providing several saliva samples; undergoing neuropsychological testing, in which participants will solve different types of problems and be interviewed about their emotional and social experiences; and undergoing a physical exam and blood draw.

Testing on the second day will include the following: an MRI scan, which will take pictures of the brain both while participants are resting and while they are performing certain tasks; more neuropsychological testing similar to that from the day before; and questionnaires about emotional and social experiences. A family member will also be asked to fill out a questionnaire about the participant. On 2 other days, participants will be asked to collect saliva samples while at their homes and send the samples to the study researchers. In addition, the researchers will keep in contact with participants in case any follow-up is needed over the next few years.

02

Conditions studied

  • Fragile X Premutation

Keywords

  • Fragile X Premutation
  • FMR1
  • Premutation
  • Fragile X
  • Brain Function
03

In context

Lead sponsor

University of California, Davis is the lead sponsor of 798 studies on the registry; 146 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 43 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Members of the general population, those with the fragile X premutation, and the brothers of those with the fragile X premutation

Inclusion criteria

  • Possesses FMR1 premutation or is part of the general population control group
  • Normal or corrected vision
  • Speaks English

Exclusion criteria

Exclusion Criteria:

  • Presence of contraindication for brain MRI, such as having metal in the body
  • Presence of a major medical condition, such as kidney, heart, or liver disease
  • Presence of a neurological disorder
  • Current alcohol or drug abuse or dependence
  • History of head trauma
  • History of brain infection
  • Medication affecting cerebral blood flow
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
110 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • 1

    Men with the fragile X premutation

  • 2

    Healthy men

  • 3

    Brothers of men with the fragile X premutation

06

What researchers measure

Primary outcomes

  1. Amygdala and hippocampus volume and function

    Time frame: Age at time of visit

07

Study locations

1 site
  • M.I.N.D. Institute, U.C. Davis
    Sacramento, California 95817, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00879502
Lead sponsor
University of California, Davis
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Apr 10, 2009
Start date
Jun 2007
Primary completion
Feb 2013
Completion
Feb 2013
Last update
May 30, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion